Dicerna Pharmaceuticals Valuation

Dicerna Pharmaceuticals Investor Information

About 89.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.63. Dicerna Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Dicerna Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Dicerna Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.

Dicerna Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Dicerna Pharmaceuticals has an asset utilization ratio of 306.36 percent. This suggests that the Company is making $3.06 for each dollar of assets. An increasing asset utilization means that Dicerna Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Dicerna Pharmaceuticals Ownership Allocation

Dicerna Pharmaceuticals holds a total of 77.91 Million outstanding shares. The majority of Dicerna Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dicerna Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dicerna Pharmaceuticals. Please pay attention to any change in the institutional holdings of Dicerna Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Dicerna Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 192.85 M. Net Loss for the year was (124.44 M) with loss before overhead, payroll, taxes, and interest of (41.08 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.